Testing APPA-1 in Healthy Subjects and Osteoarthritis Patients

To determine the safety and tolerability of ascending single and multiple oral doses of APPA-1 in healthy subjects and osteoarthritis patients. To determine the single and multiple oral dose pharmacokinetics of APPA-1 constituents (paeonol/apocynin) in healthy subjects and osteoarthritis patients. To determine the effect of food on the single oral dose pharmacokinetics of APPA-1 constituents (paeonol/apocynin) in healthy subjects. To determine the effect of gender on the single oral dose pharmacokinetics of APPA-1 constituents (paeonol/apocynin) in healthy subjects. To determine the multiple oral dose pharmacodynamics of APPA-1 in osteoarthritis patients.

NCT Number	NCT07429565
Lead Sponsor	University of Liverpool Collaborators: AKL Research and Development
Conditions	Osteoarthritis
Enrollment	40 participants
Start Date	2018-04-09
Primary Completion	2018-12-31 (estimated)
Study Completion	2018-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-24